Search

The article reports that the European Union and Canada have agreed to exchange confidential information about the authorization and safety of medicines. The agreement was signed between the European Commission, the European Medicines Agency (EMEA), and the Health Products and Food Branch of Health Canada. The deal is expected to accelerate access to innovative drugs and improve performance and safety of drugs. Examples of information that can be exchanged are position papers on future legislation and scientific advice on product development.

The article reports that the European Union and Canada has entered into an agreement to exchange drug safety information. The agreement will allow earlier access to information, thereby strengthening public health protection in both regions. Confidential information such as regulatory guidance and scientific advice will be included in the exchanges. The agreement is expected to accelerate patients' access to innovative drugs.